Not provided
Not provided
Not provided
Not provided
Not provided
Study withdrawn prior to enrollment due to sponsor decision
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Pharmactive Biotech Products S.L.U | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
Previous research has demonstrated the effectiveness of AFFRONEYE® / CROCUVIS+® dietary supplement, based on saffron extract, in the proper functioning of visual health, for example, against the development of glaucoma. The main objective of this study is to compare the results of clinical tests that evaluate signs and symptoms for the diagnosis of dry eye, between two groups (some that take the dietary supplement and others a placebo), in a sample of university workers and students who suffer from dry eye.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Saffron extract (Crocus sativus) | Experimental | Daily intake of one tablet for 84 days. |
|
| Placebo | Placebo Comparator | Daily intake of one tablet for 84 days. This tablet is organoleptically indistinguishable from the experimental tablet. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Saffron extract (Crocus sativus) | Dietary Supplement | Daily intake of one tablet for 84 days. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Changes from baseline dry eye symptoms at 28, 56 and 84 days | Measured with Ocular Surface Disease Index (OSDI, adapted version to spanish). It consists of 12 items that assess symptoms, functional limitations, and environmental factors related to dry eye. The score ranges from 0 to 100 (worst). Each item is evaluated on a 4-point Likert scale (from 0 to 4). The final score is obtained from (the sum of scores for all questions answered x 25) and divide to total number of questions answered (do not included questions answered N/A); dry eye symptoms are considered from ≥ 13 points. | 0 (baseline), 28, 56 and 84 days |
| Changes with respect to baseline NIBUT at 28, 56 and 84 days | Non-Invasive tear BreakUp Time (NIBUT). It is measured with the Keratograph 5M topographer. It is used to assess tear film stability. It is a non-invasive method to observe and detect the tear film break-up time (measured in seconds). In this case, fluorescein staining can be dispensed with, thus eliminating any influence it may have on the tear film and the results. The region and time course of tear film rupture are automatically measured without user intervention. The software analyses the Placido projecting rings on the tear film and automatically detects any distortion or discontinuity in the reflected annular pattern. The results are recorded with respect to time and space, and translated into a colour-coded map. A positive finding has been reported to be a value <10 s. | 0 (baseline), 28, 56 and 84 days |
| Changes with respect to baseline TMH at 28, 56 and 84 days | Tear Meniscus Height (TMH). It is measured with the Keratograph 5M topographer. It assesses the height of the lacrimal meniscus (measured in millimetres). Firstly, it provides information on the secretory capacity of the main lacrimal gland and secondly, it may indicate a high evaporation rate, which may, for example, be due to an insufficient lipid layer. It is measured with a ruler from the point of the lower lid margin (below the centre of the pupil) to the upper edge of the lacrimal meniscus. A positive finding has been reported to be a value <0.2 mm. | 0 (baseline), 28, 56 and 84 days |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Alicante | San Vicent del Raspeig | Alicante | 03690 | Spain |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D015352 | Dry Eye Syndromes |
| ID | Term |
|---|---|
| D007766 | Lacrimal Apparatus Diseases |
| D005128 | Eye Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo | Dietary Supplement | Daily intake of one tablet for 84 days. |
|
| Changes with respect to baseline ocular surface stainings at 28, 56 and 84 days | Ocular surface stains are used to assess epithelial damage to the cornea, conjunctiva, and lid margin. To assess corneal epithelial damage, a fluorescein strip is wet with saline, and a drop is instilled inside the lower temporal lid. Optimal viewing is 1-3 minutes after instillation. A positive result is >5 corneal spots. To assess conjunctival and lid margin damage, a lissamine green strip is wet with saline, and a drop is instilled inside the lower temporal lid. The observation should occur between 1 and 4 min postinstillation. To assess conjunctival damage, a positive score is > 9 conjunctival spots. To assess lid margin damage, ≥2 mm in length and/or ≥25% sagittal width is a positive score. | 0 (baseline), 28, 56 and 84 days |
| Changes with respect to baseline lipid layer of the tear film at 28, 56 and 84 days | The thickness of the lipid layer is not uniform throughout its structure and is examined by observing an interferential phenomenon with Keratograph 5M topographer. The ideal pattern is yellow to blue color at around 80-100nm. If excessively colored patterns are observed, this refers to a greater lipid film thickness >100nm. If, on the other hand, the pattern is gray-white, it indicates a thin or absent lipid layer, causing greater evaporation. | 0 (baseline), 28, 56 and 84 days |
| Changes with respect to baseline MGD at 28, 56 and 84 days | Meibomian Gland Dysfunction (MGD). The morphological changes of these glands are evaluated using the Keratograph 5M topographer using integrated infrared diodes that allow illumination of the everted eyelids. The Meibomian glands are located in the tarsal conjunctiva of the upper and lower eyelids and have the function of producing an oily substance (meibum), which forms the lipid layer of the tear film, protecting it against evaporation of its aqueous phase. The number of meibomian glands should be evaluated in the photographs taken; the larger the area without glands, the greater the DGM. | 0 (baseline), 28, 56 and 84 days |
| Changes from baseline osmolarity at 28, 56 and 84 days | Measured with the Tearlab osmometer. A positive result is considered to be ≥308 mOsm/L in either eye or an interocular difference >8 mOsm/L. | 0 (baseline), 28, 56 and 84 days |